BCM
NKTR icon

BlueCrest Capital Management’s Nektar Therapeutics NKTR Stock Holding History

BlueCrest Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-528
Closed -$282K – 644
2019
Q2 		$282K Buy
+528
New +$265K 0.02% 295
2018
Q4 		– Sell
-2,139
Closed -$1.96M – 1234
2018
Q3 		$1.96M Sell
2,139
-8,390
-80% -$7.16M 0.05% 265
2018
Q2 		$7.71M Buy
10,529
+10,049
+2,094% +$11.6M 0.2% 107
2018
Q1 		$764K Buy
+480
New +$618K 0.02% 576

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlueCrest Capital Management's NKTR Position: Q3 2019 in Review

BlueCrest Capital Management sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 528 shares — an estimated $282K sold.

BlueCrest Capital Management first reported a position in NKTR in Q1 2018 and held it in 4 quarters. The position peaked at $7.71M in Q2 2018. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • BlueCrest Capital Management reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 528 Nektar Therapeutics shares in Q3 2019, an estimated $282K.
  • BlueCrest Capital Management first reported a position in Nektar Therapeutics in Q1 2018 and held it in 4 quarters.
  • BlueCrest Capital Management's Nektar Therapeutics position peaked at $7.71M in Q2 2018.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on BlueCrest Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.